Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

por Mainz, Jochen G., Zagoya, Carlos, Polte, Louise, Naehrlich, Lutz, Sasse, Lenny, Eickmeier, Olaf, Smaczny, Christina, Barucha, Anton, Bechinger, Lilith, Duckstein, Franziska, Kurzidim, Ludwik, Eschenhagen, Patience, Caley, Laura, Peckham, Daniel, Schwarz, Carsten
Publicado 2023

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

por Mainz, Jochen G., Zagoya, Carlos, Polte, Louise, Naehrlich, Lutz, Sasse, Lenny, Eickmeier, Olaf, Smaczny, Christina, Barucha, Anton, Bechinger, Lilith, Duckstein, Franziska, Kurzidim, Ludwik, Eschenhagen, Patience, Caley, Laura, Peckham, Daniel, Schwarz, Carsten
Publicado 2022

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

por Mainz, Jochen G., Barucha, Anton, Huang, Pu, Bechinger, Lilith, Duckstein, Franziska, Polte, Louise, Sadrieh, Pauline, Nährlich, Lutz, Eickmeier, Olaf, Van Dullemen, Suzanne, Eschenhagen, Patience, Schwarz, Carsten, Lüth, Stefan, Zagoya, Carlos, Graepler-Mainka, Ute
Publicado 2023